{"schema_version":"1.0","type":"article","title":"第一三共最貴的一課：ADC 爆款之後，產能豪賭如何反噬？","url":"https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson.md","lang":"zh-Hant","date":"2026-05-17","publish_at":"2026-05-17T10:30:00+08:00","updated_at":"2026-05-17","category":"商業分析系列","topic":"臨床與 CMC","tags":["第一三共","ADC","DXd","Enhertu","CDMO","CMO","供應鏈","浩鼎","永昕"],"summary":"第一三共因 ADC 供應鏈與產能承諾認列高額費用，提醒新藥公司與 CDMO：pipeline 要折現，產能也要折現。","key_points":[],"facts":[],"sections":["ADC 不只比臨床，也比產能","第一三共押注的不是一條產品線，而是一整套 DXd 帝國","臨床失利如何變成產能成本","第一三共最貴的一課：供應鏈也需要風險折現","台灣可以對照誰？","真正的重點","參考資料 / 延伸閱讀"],"references":[],"images":[{"alt":"第一三共 ADC 產能豪賭的核心：DXd 平台爆款、後續管線、CMO 合約與小田原工廠投資，在臨床節奏修正後轉化為高額成本。","url":"https://drugnews.com.tw/assets/articles/daiichi-sankyo-adc-capacity-lesson/dcard-01.png"},{"alt":"第一三共 DXd ADC 資產與合作布局：Enhertu、Datroway、HER3-DXd、I-DXd 與 R-DXd 共同構成產能預期。","url":"https://drugnews.com.tw/assets/articles/daiichi-sankyo-adc-capacity-lesson/dcard-02.png"},{"alt":"第一三共認列的 ADC 供應鏈成本：CMO 補償費用準備金與小田原工廠 ADC 設備減損，合計約 950 億日圓。","url":"https://drugnews.com.tw/assets/articles/daiichi-sankyo-adc-capacity-lesson/dcard-03.png"},{"alt":"ADC 供應鏈也需要風險折現：臨床成功率、監管時間、安全性標籤、商業化爬坡與最低採購義務都會影響產能價值。","url":"https://drugnews.com.tw/assets/articles/daiichi-sankyo-adc-capacity-lesson/dcard-05.png"},{"alt":"台灣 ADC 與 CDMO 對照：浩鼎代表 ADC 新藥開發主線，永昕代表 ADC / 生物藥製造與 CDMO 主線。","url":"https://drugnews.com.tw/assets/articles/daiichi-sankyo-adc-capacity-lesson/dcard-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/daiichi-sankyo-adc-capacity-lesson/dcard-01.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-17）。第一三共最貴的一課：ADC 爆款之後，產能豪賭如何反噬？。https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-17-daiichi-sankyo-adc-capacity-lesson-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}